American Nutritional Giant Acquires Leading UK Probiotics Firm
In a significant move within the global health supplements industry, Symprove, one of Britain's foremost home-grown probiotic manufacturers, is being sold to its American counterpart, Metagenics. Sky News has exclusively learned that the deal, expected to be formally announced imminently, underscores the surging international appetite for gut-health and wellness products.
From Surrey Farm to Global Brand
The transaction marks a pivotal moment for Symprove, which was founded in 2010 by entrepreneur Barry Smith on his Surrey farm. Initially developed as a water-based formula for farm animals, Smith soon recognised its potential benefits for human digestive health. Over the past decade and a half, the company has evolved into a major British brand, frequently cited as the probiotic most recommended by healthcare professionals across the UK.
Boosting International Reach
City sources indicate that the acquisition will deliver a substantial financial return for bd-capital, the private equity firm that has backed Symprove since 2020, along with other shareholders. Under bd-capital's stewardship, led by Chief Executive Will Bowler, Symprove has experienced rapid annual sales growth, transforming into Europe's largest subscription-based business of its kind. The company's products are noted for offering effective relief for conditions such as Irritable Bowel Syndrome (IBS) and gastric symptoms associated with diseases like Parkinson's.
Symprove had reportedly attracted considerable takeover interest from various strategic and financial investors. However, its owners ultimately prioritised securing a buyer capable of expanding the brand's international footprint while preserving its rigorous scientific foundation. Metagenics, a New Jersey-based nutritional supplements provider backed by private investment firm Gryphon Investors, emerged as the chosen partner. Financial advisors Jefferies oversaw the sale for Symprove's owners, while Greenhill and Spayne Lindsay advised Gryphon Investors on the acquisition.
A Landmark Exit
This deal represents the first successful exit for bd-capital, a private equity entity co-founded by Richard Baker, the former chief executive of Boots, and Andy Dawson, a seasoned figure from Advent International. The specific financial terms of the acquisition remain undisclosed at this stage. Neither bd-capital nor Symprove were available for comment on Wednesday evening as final preparations for the announcement were underway.
The takeover reflects a broader trend of escalating consumer focus on gut health and its profound impact on overall physical and mental wellbeing, driving consolidation and investment within the global supplements market.
